Company

Opthea Limited

Headquarters: South Yarra, VIC, Australia

CEO: Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.

ASX: OPT -7.89%

Market Cap

A$241.3 Million

AUD as of July 1, 2024

US$160.7 Million

Market Cap History

Opthea Limited market capitalization over time

Evolution of Opthea Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Opthea Limited

Detailed Description

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Opthea Limited has the following listings and related stock indices.


Stock: ASX: OPT wb_incandescent

Stock: NASDAQ: OPT wb_incandescent

Details

Headquarters:

650 Chapel Street

Suite 0403 Level 4

South Yarra, VIC 3141

Australia

Phone: 61 3 9826 0399

Fax: 61 3 9824 0083